ALDP001 USFDA
Alixer Nexgen Successfully Clears U.S. FDA IND for ALDP001 for the Treatment of Seasonal and Perennial Allergic Rhinitis Alixer Nexgen Therapeutics Ltd announced that the U.S. FDA has accepted its IND application for ALDP001 for the treatment of seasonal and perennial allergic rhinitis (AR), marking a significant milestone in advancing its first‑in‑class pipeline. ALDP001, a […]
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!